M-type Phospholipase A2 Receptor Autoantibodies and Renal Function in Patients with Primary Membranous Nephropathy

被引:89
作者
Hoxha, Elion [1 ]
Harendza, Sigrid [1 ]
Pinnschmidt, Hans [2 ]
Panzer, Ulf [1 ]
Stahl, Rolf A. K. [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 3, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2014年 / 9卷 / 11期
关键词
CYCLOPHOSPHAMIDE; ANTIBODIES; RITUXIMAB; PROGNOSIS; ELISA;
D O I
10.2215/CJN.03850414
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Loss of renal function in patients with primary membranous nephropathy cannot be reliably predicted by laboratory or clinical markers at the time of diagnosis. M-type phospholipase A(2) receptor autoantibodies have been shown to be associated with changes in proteinuria. Their eventual effect on renal function, however, is unclear. Design, setting, participants, & measurements In this prospective, open, multicenter study, the potential role of M-type phospholipase A(2) receptor autoantibodies levels on the increase of serum creatinine in 118 consecutive patients with membranous nephropathy and positivity for serum M-type phospholipase A(2) receptor autoantibodies was analyzed. Patients were included in the study between April of 2010 and December of 2012 and observed until December of 2013. The clinical end point was defined as an increase of serum creatinine by >= 25% and serum creatinirte reaching mg/dl. Results Patients were divided into tertiles according to their M-type phospholipase A(2) receptor autoantibody levels at the time of inclusion in the study: tertile 1 levels=20-86 units/ml (low), tertile 2 levels=87-201 units/ml (medium), and tertile 3 levels >= 202 units/ml (high). The median follow-up time of all patients in the study was 27 months (interquartile range=18-33 months). The clinical end point was reached in 69% of patients with high M-type phospholipase A(2) receptor autoantibodies levels (tertile 3) but only 25% of patients with low M-type phospholipase A(2) receptor autoantibodies levels. The average time to reach the study end point was 17.7 months in patients with high M-type phospholipase A(2) receptor autoantibodies levels and 30.9 months in patients with low M-type phospholipase A(2) receptor autoantibodies levels. A multivariate Cox regression analysis showed that high M-type phospholipase A(2) receptor autoantibodies levels in addition to men and older age are an independent predictor for progressive loss of renal function. Conclusions High M-type phospholipase A(2) receptor autoantibodies levels were associated with more rapid loss of renal function in this cohort of patients with primary membranous nephropathy and therefore, could be helpful for treatment decisions.
引用
收藏
页码:1883 / 1890
页数:8
相关论文
共 21 条
  • [1] [Anonymous], 1968, SOMMERS PATHOLOGY AN
  • [2] Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
    Beck, Laurence H., Jr.
    Fervenza, Fernando C.
    Beck, David M.
    Bonegio, Ramon G. B.
    Malik, Fahim A.
    Erickson, Stephen B.
    Cosio, Fernando G.
    Cattran, Daniel C.
    Salant, David J.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (08): : 1543 - 1550
  • [3] M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
    Beck, Laurence H., Jr.
    Bonegio, Ramon G. B.
    Lambeau, Gerard
    Beck, David M.
    Powell, David W.
    Cummins, Timothy D.
    Klein, Jon B.
    Salant, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01) : 11 - 21
  • [4] THE LONG-TERM PROGNOSIS OF THE PRIMARY GLOMERULONEPHRITIDES - A MORPHOLOGICAL AND CLINICAL ANALYSIS OF 1747 CASES
    BOHLE, A
    WEHRMANN, M
    BOGENSCHUTZ, O
    BATZ, C
    VOGL, W
    SCHMITT, H
    MULLER, CA
    MULLER, GA
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1992, 188 (07) : 908 - 924
  • [5] The impact of sex in primary glomerulonephritis
    Cattran, Daniel C.
    Reich, Heather N.
    Beanlands, Heather J.
    Miller, Judith A.
    Scholey, James W.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) : 2247 - 2253
  • [6] Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial
    Cattran, DC
    Appel, GB
    Hebert, LA
    Hunsicker, LG
    Pohl, MA
    Hoy, WE
    Maxwell, DR
    Kunis, CL
    [J]. KIDNEY INTERNATIONAL, 2001, 59 (04) : 1484 - 1490
  • [7] Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications
    Cattran, DC
    Pei, Y
    Greenwood, CMT
    Ponticelli, C
    Passerini, P
    Honkanen, E
    [J]. KIDNEY INTERNATIONAL, 1997, 51 (03) : 901 - 907
  • [8] Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy
    Daehnrich, Cornelia y
    Komorowski, Lars
    Probst, Christian
    Seitz-Polski, Barbara
    Esnault, Vincent
    Wetzels, Jack F.
    Hofstra, Julia M.
    Hoxha, Elion
    Stahl, Rolf A.
    Lambeau, Gerard
    Stoecker, Winfried
    Schlumberger, Wolfgang
    [J]. CLINICA CHIMICA ACTA, 2013, 421 : 213 - 218
  • [9] Diagnosis and natural course of membranous nephropathy
    Glassock, RJ
    [J]. SEMINARS IN NEPHROLOGY, 2003, 23 (04) : 324 - 332
  • [10] Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy
    Hofstra, Julia M.
    Debiec, Hanna
    Short, Colin D.
    Pelle, Tinnothee
    Kleta, Robert
    Mathieson, Peter W.
    Ronco, Pierre
    Brenchley, Paul E.
    Wetzels, Jack F.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (10): : 1735 - 1743